Cytokines as markers of osteolysis in the diagnostics of patients with bone metastases;Cytokiny jako markery osteolizy w diagnostyce pacjentów z przerzutami nowotworowymi do kos̈ci

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 668-675

  Groblewska, Magdalena ^a   Mroczko, Barbara ^a   Czygier, Małgorzata ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bone metastases; Bone turnover markers; Cytokines; Neoplastic osteolysis

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

BLOOD; BONE TUMOR; HUMAN; METASTASIS; OSTEOLYSIS; REVIEW;

BONE NEOPLASMS; CYTOKINES; HUMANS; INTERLEUKIN-6; MACROPHAGE COLONY-STIMULATING FACTOR; OSTEOLYSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63149166912     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Adler H.L., McCurdy M.A., Kattan M.W., Timme T.L., Scardino P.T., Thompson T.C.: Elevated levels of circulating interleukin-6 and transforming growth factor-b1 in patients with metastatic prostatic carcinoma. J. Urol., 1999; 161: 182-187
2. Asschert J.G., Vellenga E., Hollema H., van der Zee A.G., de Vries E.G.: Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1 b (IL-1 b), interleukin-11 (IL-11) and tumour necrosis factor-A (TNF-a) in p53-characterised human ovarian carcinomas. Eur. J. Cancer, 1997; 33: 2246-2251
3. Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A.: Tumor necrosis factor-A induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem., 2000; 275: 4858-4864
4. Bellone S., Watts K., Cane' S., Palmieri M., Cannon M.J., Burnett A., Roman J.J., Pecorelli S., Santin A.D.: High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol. Oncol., 2005; 98: 92-98
5. Berberoglu U., Yildirim E., Celen O.: Serum levels of tumor necrosis factor a correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int. J. Biol. Markers, 2004; 19: 130-134
6. Brozek W., Bises G., Girsch T., Cross H.S., Kaiser H.E., Peterlik M.: Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur. J. Cancer, 2005; 41: 2347-2354
7. Cosenza L., Gorgun G., Urbano A., Foss F.: Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signal., 2002; 14: 317-325
8. Csiszár A., Szentes T., Haraszti B., Balázs A., Petrányi G.G., Pócsik E.: The pattern of cytokine gene expression in human colorectal carcinoma. Pathol. Oncol. Res., 2004; 10: 109-116
9. Derynck R., Akhurst R.J., Balmain A.: TGF-b signaling in tumor suppression and cancer progression. Nat. Genet., 2001; 29: 117-129
10. Dumont N., Arteaga C.L.: Targeting the TGF beta signaling network in human neoplasia. Cancer Cell, 2003; 3: 531-536
11. Eastham J.A., Truong L.D., Rogers E., Kattan M., Flanders K.C., Scardino P.T., Thompson T.C.: Transforming growth factor-b 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab. Invest., 1995; 73: 628-635
12. El Hajj Dib I., Gallet M., Mentaverri R., Sévenet N., Brazier M., Kamel S.: Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur. J. Pharmacol., 2006; 551: 27-33
13. Garcia-Tunón I., Ricote M., Ruiz A., Fraile B., Paniagua R., Royuela M.: IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology, 2005; 47: 82-89
14. Guise T.A., Yin J.J., Taylor S.D., Kumagai Y., Dallas M., Boyce B.F., Yoneda T., Mundy G.R.: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human brest cancer-mediated osteolysis. J. Clin. Invest., 1996; 98: 1544-1549
15. Hauschka P.V., Chen T.L., Mavrakos A.E.: Polypeptide growth factors in bone matrix. Ciba Found. Symp., 1988; 136: 207-225
16. Jambhekar NA., Borges A.: Metastases involving bone pathology and genetics of tumors of soft tissue and bone. WHO Classification of Tumors IARC Press Lyon, 2002
17. Kamiñska J., Kowalska M., Kotowicz B., Fuksiewicz M., Glogowski M., Wojcik E., Chechliñska M., Steffen J.: Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF-an independent prognostic factor. Oncology, 2006; 70: 115-125
18. Kamiñska J., Kowalska M., Rysiñska A.: Cytokiny w surowicy krwi u chorych na nowotwory zoliwe. Nowotwory, 1999; 49: 21-26
19. Katsumata N., Eguchi K., Fukuda M., Yamamoto N., Ohe Y., Oshita F., Tamura T., Shinkai T., Saijo N.: Serum levels of cytokines in patients with untreated primary lung cancer. Clin. Cancer Res., 1996; 2: 553-559
20. Kominsky S.L, Doucet M., Brady K., Weber K.L.: TGF-b promotes the establishment of renal cell carcinoma bone metastasis. J. Bone Miner. Res., 2007; 22: 37-44
21. Koseki T., Gao Y., Okahashi N., Murase Y., Tsujisawa T., Sato T., Yamato K., Nishihara T.: Role of TGF-b family in osteoclastogenesis induced by RANKL. Cell. Signal., 2002; 14: 31-36
22. Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G.D.: IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol., 1990; 144: 4226-4230
23. Malik S.T.: Tumour necrosis factor: roles in cancer pathophysiology. Semin. Cancer Biol., 1992; 3: 27-33
24. Mancino A.T., Klimberg V.S., Yamamoto M., Manolagas S.C., Abe E.: Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J. Surg. Res., 2001; 100: 18-24
25. McDermott R.S., Deneux L., Mosseri V., Védrenne J., Clough K., Fourquet A., Rodriguez J., Cosset J.M., Sastre X., Beuzeboc P., Pouillart P., Scholl S.M.: Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur. Cytokine Netw., 2002; 13: 121-127
26. Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T., Kishimoto T.: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett., 1989; 250: 607-610
27. Mroczko B., Szmitkowski M.: Czynnik wzrostu kolonii makrofagowych (M-CSF) w diagnostyce i monitorowaniu niedrobnokomórkowego raka puca (NSCLC). Pol. Arch. Med. Wewn., 2001; 105: 203-209
28. Mroczko B., Szmitkowski M., Okulczyk B.: Granulocyte-colony stimulating factor (G-CSF) and macrophage-colony stimulating factor (M-CSF) in colorectal cancer patients. Clin. Chem. Lab. Med., 2002; 40: 351-355
29. Mundy G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2002; 2: 584-593
30. Negrier S., Perol D., Menetrier-Caux C., Escudier B., Pallardy M., Ravaud A., Douillard J.Y., Chevreau C., Lasset C., Blay J.Y.; Groupe Francais d'Immunotherapie: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J. Clin. Oncol., 2004; 22: 2371-2378
31. Ohno H., Kubo K., Murooka H., Kobayashi Y., Nishitoba T., Shibuya M., Yoneda T., Isoe T.: A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol. Cancer Ther., 2006; 5: 2634-2643
32. Pederson L., Winding B., Foged N.T., Spelsberg T.C., Oursler M.J.: Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res., 1999; 59: 5849-5855
33. Pei X.H., Nakanishi Y., Takayama K., Bai F., Hara N.: Granulocyte, granulocyte-macrophage and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br. J. Cancer, 1999; 79: 40-46
34. Pfeilschifter J., Mundy G.R.: Modulation of type b transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA, 1987; 84: 2024-2028
35. Pusztai L., Clover L.M., Cooper K., Starkey P.M., Lewis C.E., McGee J.O.: Expression of tumour necrosis factor a and its receptors in carcinoma of the breast. Br. J. Cancer, 1994; 70: 289-292
36. Rasmussen A.A., Cullen K.J.: Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res. Treat., 1998; 47: 219-233
37. Riggs B.L., Parfitt A.M.: Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res., 2005; 20: 177-184
38. Roato I., Brunetti G., Gorassini E., Grano M., Colucci S., Bonello L., Buffoni L., Manfredi R., Ruffini E., Ottaviani D., Ciuffreda L., Mussa A., Ferracini R.: IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS ONE, 2006; 1: e124
39. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., Pacifici R.: Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA, 2001; 98: 13960-13965
40. Roodman G.D.: Biology of osteoclast activation in cancer. J. Clin. Oncol., 2001; 19: 3562-3571
41. Savarese D.M., Valinski H., Quesenberry P., Savarese T.: Expression and function of colony-stimulating factors and their receptors in human prostate carcinoma cell lines. Prostate, 1998; 34: 80-91
42. Scholl S.M., Bascou C.H., Mosseri V., Olivares R., Magdelenat H., Dorval T., Palangié T., Validire P., Pouillart P., Stanley E.R.: Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br. J. Cancer, 1994; 69: 342-346
43. Shaarawy M., Abdel-Aziz O.: Serum tumour necrosis factor a levels in benign and malignant lesions of the endometrium in postmenopausal women. A preliminary study. Acta Oncol., 1992; 31: 417-420
44. Sherr C.J.: Colony-stimulating factor-1 receptor. Blood, 1990; 75: 1-12
45. Songür N., Kuru B., Kalkan F., Ozdilekcan C., Cakmak H., Hizel N.: Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori, 2004; 90: 196-200
46. Szlosarek P.W., Grimshaw M.J., Kulbe H., Wilson J.L., Wilbanks G.D., Burke F., Balkwill F.R.: Expression and regulation of tumor necrosis factor a in normal and malignant ovarian epithelium. Mol. Cancer Ther., 2006; 5: 382-390
47. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., Taga T., Kishimoto T., Suda T.: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA, 1993; 90: 11924-11928
48. Trinder P., Seitzer U., Gerdes J., Seliger B., Maeurer M.: Constitutive and IFN-g regulated expression of IL-7 and IL-15 in human renal cell cancer. Int. J. Oncol., 1999; 14: 23-31
49. Wang Y., Yang J., Gao Y., Du Y., Bao L., Niu W., Yao Z.: Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell. Mol. Immunol., 2005; 2: 365-372
50. Weber K., Doucet M., Kominsky S.: Renal cell carcinoma bone metastasis-elucidating the molecular targets. Cancer Metastasis Rev., 2007; 26: 691-704
51. Weitzmann M.N., Cenci S., Rifas L., Brown C., Pacifici R.: Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood, 2000; 96: 1873-1878
52. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K.: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 1998; 139:1329-1337
53. Yee L.D., Liu L.: The constitutive production of colony stimulating factor 1 by invasive human breast cancer cells. Anticancer Res., 2000; 20: 4379-4383
54. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., Massagué J., Mundy G.R., Guise T.A.: TGF-b signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest., 1999; 103: 197-206
55. Yu H., Rohan T.: Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst., 2000; 92: 1472-1489